Cardio Diagnostics Valuation
| CDIOW Stock | USD 0.1 0 2.10% |
Cardio Diagnostics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Cardio Diagnostics from analyzing the firm fundamentals such as Revenue of 17.07 K, return on equity of -2.93, and Operating Margin of (162.96) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cardio Diagnostics' price fluctuation is out of control at this time. Calculation of the real value of Cardio Diagnostics is based on 3 months time horizon. Increasing Cardio Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cardio stock is determined by what a typical buyer is willing to pay for full or partial control of Cardio Diagnostics Holdings. Since Cardio Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cardio Stock. However, Cardio Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0979 | Real 0.074 | Hype 0.11 | Naive 0.1 |
The intrinsic value of Cardio Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cardio Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cardio Diagnostics Holdings helps investors to forecast how Cardio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cardio Diagnostics more accurately as focusing exclusively on Cardio Diagnostics' fundamentals will not take into account other important factors: Cardio Diagnostics Total Value Analysis
Cardio Diagnostics Holdings is currently estimated to have takeover price of 0 with market capitalization of 0, debt of 1.26 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cardio Diagnostics fundamentals before making investing decisions based on enterprise value of the companyCardio Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cardio Diagnostics has an asset utilization ratio of 0.38 percent. This indicates that the Company is making $0.003824 for each dollar of assets. An increasing asset utilization means that Cardio Diagnostics Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Cardio Diagnostics Profitability Analysis
The company reported the revenue of 17.07 K. Net Loss for the year was (8.38 M) with profit before overhead, payroll, taxes, and interest of 0.About Cardio Diagnostics Valuation
Our relative valuation model uses a comparative analysis of Cardio Diagnostics. We calculate exposure to Cardio Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cardio Diagnostics's related companies.Cardio Diagnostics Inc. develops and manufactures a genetic and epigenetic based test for prevention and detection of cardiovascular disease. Cardio Diagnostics Inc. was founded in 2017 and is based in Chicago, Illinois. Cardio Diagnostics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Cardio Diagnostics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cardio Diagnostics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 12.7 M |
Additional Tools for Cardio Stock Analysis
When running Cardio Diagnostics' price analysis, check to measure Cardio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardio Diagnostics is operating at the current time. Most of Cardio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Cardio Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardio Diagnostics' price. Additionally, you may evaluate how the addition of Cardio Diagnostics to your portfolios can decrease your overall portfolio volatility.